Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Hannu Koistinen"'
Autor:
Maria H. Jäntti, Virpi Talman, Kati Räsänen, Ilari Tarvainen, Hannu Koistinen, Raimo K. Tuominen
Publikováno v:
FEBS Open Bio, Vol 8, Iss 5, Pp 817-828 (2018)
Prostate cancer is one of the most common cancers in men. Although it has a relatively high 5‐year survival rate, development of resistance to standard androgen‐deprivation therapy is a significant clinical problem. Therefore, novel therapeutic s
Externí odkaz:
https://doaj.org/article/04c1350fde84491bb7286f40dc0a2c00
Autor:
Kati Räsänen, Kien X. Dang, Harri Mustonen, Tho H. Ho, Susanna Lintula, Hannu Koistinen, Ulf‐Håkan Stenman, Caj Haglund, Jakob Stenman
Publikováno v:
Molecular Oncology, Vol 12, Iss 2, Pp 224-238 (2018)
The mitogen‐activated protein kinase (MAPK) pathway plays a central role in colorectal cancers (CRC). In particular, BRAF V600E‐mutant tumors, which represent around 10% of CRCs, are refractory to current therapies. Overexpression and secretion o
Externí odkaz:
https://doaj.org/article/86377942144a4085994002376e60316c
Autor:
Hannu Koistinen, Ruusu‐Maaria Kovanen, Morley D. Hollenberg, Antoine Dufour, Evette S. Radisky, Ulf‐Håkan Stenman, Jyotsna Batra, Judith Clements, John D. Hooper, Eleftherios Diamandis, Oliver Schilling, Antti Rannikko, Tuomas Mirtti
Publikováno v:
IUBMB Life. 75:493-513
Since the proposition of the pro-invasive activity of proteolytic enzymes over 70 years ago, several roles for proteases in cancer progression have been established. About half of the 473 active human proteases are expressed in the prostate and many
Autor:
Timo‐Pekka K. Lehto, Ruusu‐Maaria Kovanen, Susanna Lintula, Adrian Malén, Carolin Stürenberg, Andrew Erickson, Olli‐Pekka Pulkka, Ulf‐Håkan Stenman, Eleftherios P. Diamandis, Antti Rannikko, Tuomas Mirtti, Hannu Koistinen
Publikováno v:
International Journal of Cancer.
Autor:
Carolin Stürenberg, Andrew Erickson, Adrian Malen, Hannu Koistinen, Ian G. Mills, Antti Rannikko, Tuomas Mirtti, Timo-Pekka Lehto
Publikováno v:
Lehto, T-P K, Stürenberg, C, Malén, A, Erickson, A M, Koistinen, H, Mills, I G, Rannikko, A & Mirtti, T 2021, ' Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers ', Prostate . https://doi.org/10.1002/pros.24108
BACKGROUND: Improved prognostication is needed to minimize overtreatment in grade group (GG) 2-4 prostate cancer. Our aim was to determine, at messenger RNA (mRNA) level, the performance of the genes in the commercial panels Decipher, Oncotype DX, Pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::473eafad4598f5240f161f088b18ca9a
https://ora.ox.ac.uk/objects/uuid:9d0ce665-99ea-47b8-9e93-1d291da422b6
https://ora.ox.ac.uk/objects/uuid:9d0ce665-99ea-47b8-9e93-1d291da422b6
Autor:
Ulf-Håkan Stenman, Kati Räsänen, Hannu Koistinen, Elina Lehtinen, Teijo Kuopio, Kristiina Nokelainen, Outi Itkonen, Laura Hautala
Publikováno v:
Molecular Carcinogenesis. 55:2010-2023
Inflammation promotes colorectal cancer (CRC) tumorigenesis, but the underlying molecular mechanisms are still being uncovered. Proinflammatory cytokine interleukin-6 (IL-6) stimulates survival signaling in CRC; inflammatory signals also regulate pro
Publikováno v:
American Journal of Reproductive Immunology. 69:42-170
Publikováno v:
The Prostate. 72:1588-1594
BACKGROUND Proteolytically active prostate-specific antigen (PSA or kallikrein-related peptidase 3, KLK3) has been shown to exert antiangiogenic properties. High levels of PSA in prostatic tumors may thus slow down cancer progression by inhibiting an
Publikováno v:
The Prostate. 70:482-490
BACKGROUND When secreted from the prostate, most of prostate-specific antigen (PSA) is free and enzymatically active. Upon reaching circulation, active PSA is inactivated by complex formation with protease inhibitors. To justify the use of mouse mode
Autor:
Gerd Wohlfahrt, Ping Wu, Hannu Koistinen, Juhani Lahdenperä, Johanna M. Mattsson, Ulf-Håkan Stenman
Publikováno v:
The Prostate. 68:1143-1151
Background Prostate-specific antigen (PSA or KLK3) has been shown to inhibit angiogenesis, but it might also have tumor promoting activities. Thus, it may be possible to modulate prostate cancer growth by stimulating or inhibiting the activity of PSA